human rhodopsin based optogenetic gene therapy Search Results


human rhodopsin based optogenetic gene therapy  (Acucela Inc)
90
Acucela Inc human rhodopsin based optogenetic gene therapy
Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All <t>optogenetic</t> channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])
Human Rhodopsin Based Optogenetic Gene Therapy, supplied by Acucela Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rhodopsin+based+optogenetic+gene+therapy/human+rhodopsin+based+optogenetic+gene+therapy/pmc07307607-50-6-1
Average 90 stars, based on 1 article reviews
human rhodopsin based optogenetic gene therapy - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin

doi: 10.1007/978-1-4939-7522-8_12

Figure Lengend Snippet: Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])

Article Snippet: Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants.

Techniques: Comparison, Expressing, In Vitro, Modification